Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

NCT07462377 is registered in ClinicalTrials.gov with EpiBiologics as lead sponsor.

NCT NCT07462377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07462377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
Lead sponsor
EpiBiologics
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2026
Completion date
July 31, 2029
Enrollment
110 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, epidermal growth factor, epidermal growth factor receptor, epidermal growth factor receptor gene mutation, head and neck, head and neck cancer, head and neck cancers, head and neck squamous cell cancer, head and neck squamous cell carcinoma, head and neck squamous cell carcinoma hnscc, hnscc, non small cell, non small cell lung, non small cell lung cancer, nsclc (non-small cell lung cancer)